SUMMARY The effect of low dose infusions of somatostatin on meal stimulated gastric acid secretion was studied in eight healthy volunteers by intragastric titration after a peptone test meal with radioimmunoassay control of the plasma concentrations of somatostatin and the pancreatic hormones glucagon and insulin. Infusion of somatostatin in a dose of 100 ng/kg/h, resulting in a plasma concentration of 13A4±2 1 pmol/l, inhibited acid secretion significantly, and in a dose of 800 ng/kg/h, with corresponding plasma concentration of 66-5±12-0 pmol/l the acid secretion was virtually abolished. Plasma concentrations of insulin and pancreatic glucagon decreased significantly during infusion of 200 ng/kg/h (24.5±7.5 pmol/l) and glucose concentrations increased. Serum gastrin was only significantly decreased during the highest dose of somatostatin. The range of plasma somatostatin concentrations obtained with the lower doses correspond to reported physiological variations. The results support the concept that somatostatin participates in the hormonal control of the pancreatic endocrine and the acid secretion.
The particular localisation and shape of the somatostatin-producing D-cells in the gastric epithelium and the pancreatic islets suggests that somatostatin acts as a paracrine messenger. [1] [2] [3] [4] Studies in dogs by Schusdziarra et at5 however, have indicated that somatostatin may act as a true hormone with a regulatory role in the homeostasis of ingested nutrients. Furthermore, studies in different experimental animals613 and human subjects1420 have shown that exogenous somatostatin is a potent inhibitor of gastric acid secretion and of the endocrine pancreas, and it has been suggested that somatostatin participates in the physiological control of these secretions as a hormonal mediator. 5 [20] [21] The reported effects of somatostatin may be pharmacological, however, because plasma concentrations were generally not controlled.
The present study deals with the effect of increasing doses of somatostatin on meal stimulated gastrin and gastric acid secretion under immunochemical control of the plasma concentrations of somatostatin. In addition we studied the effect on the pancreatic hormones glucagon and insulin, the secretion of which under these circumstances is moderately stimulated. 
Results
The cumulated gastic acid secretion of the control study is shown in Figure 1 . The secretory rate was constant throughout the study, even during the fourth hour. The concentration of somatostatin in plasma remained constant throughout the control study (mean value: 5.3±0-2 pmol/1).
The gastric acid secretion during the different somatostatin infusions and corresponding plasma concentrations are shown in Figure 2 . A significant inhibition of acid secretion is seen already during infusion of somatostatin in a dose of 100 ng/kg/h with corresponding mean plasma concentration of 13-4±2x1 pmol/l. During infusion of the highest dose of somatostatin resulting in mean plasma concentrations of 66-5±12x0 pmol/l the gastric acid secretion was nearly abolished.
Plasma insulin concentrations decreased with increasing doses of somatostatin and the same was true for pancreatic glucagon as shown in Figure 3 during the highest dose of somatostatin a significant decrease (p<O0O5) was noted. Blood glucose increased significantly (p<OOI) during all somatostatin doses.
Discussion
The study confirms that exogenous somatostatin is a potent inhibitor of gastric acid secretion in man, '5-19 and shows that somatostatin inhibits acid secretion in a dose dependent manner. The doses used in the present study are lower than those of previous studies. The minimum dose required for significant inhibition was 100 ng/kg/h, resulting in a plasma concentration of 13-4 pmol/l. The increase, which is less than 10 pmol/l, may be considered physiological 
